Table 1.
Case (135) | Control (69) | P-value | |
---|---|---|---|
Age (SD) Mean (SD) | 49.7 (9.9) | 49.8 (9.6) | 0.96 |
Menopausal status N (%) | 0.87 | ||
Pre 114 | 76 (56.3%) | 38 (55.1%) | |
Post 90 | 59 (43.7%) | 31 (44.9%) | |
Histology Class N (%) | 0.78 | ||
aClass 1 115 | 79 (58.5%) | 40 (58.0%) | |
51 (37.8%) | 25 (36.2%) | bClass 2 75 | |
NA 10 | 5 (3.7%) | 4 (5.8%) | |
ER status N (%) | |||
Positive | 109 (80.8%) | ||
Negative | 23 (17.0%) | ||
Low | 3 (2.2%) | ||
Follow-up years (SD) | 7.3 (4.4) | 16.6 (5.4) | <0.01 |
Has matched germline (%) | 20 (14.8%) | 6 (8.7%) | |
Has matched cancer (%) | 10 (7.4%) |
aClass 1/non-proliferative: “Non-proliferation” and “Benign, NOS”.
bClass 2/proliferative: “Proliferative lesion without atypia” (includes non-atypical hyperplasia, radial scar, sclerosing adenosis).